Study Finds Birth Hypoxia May Increase ADHD Likelihood
January 27, 2026
Brand Name :
Inflectra, Ixifi, Remicade, Renflexis, Avsola
Synonyms :
Class :
Antirheumatics, TNF alfa inhibitors
Dosage Forms & Strengths
Injection for reconstitution
100mg/vial
Administer dose of 3 mg/kg intravenously at 0, 2, and 6 weeks then administer every 8 weeks
Administer dose of 5 mg/kg intravenously at 0, 2, and 6 weeks then administer every 8 weeks
Start dose at week 10 or thereafter: Administer dose of 120 mg subcutaneously every 2 weeks
Administer dose of 5 mg/kg intravenously at 0, 2, and 6 weeks then administer every 6 weeks
Dosage Forms & Strengths
Injection for reconstitution
100mg/vial
For <6 years old: Not studied
For ≥6 to 17 years old: Administer dose of 5 mg/kg intravenously at 0, 2, and 6 weeks then every 8 weeks
For <6 years old: Not studied
For ≥6 years old: Administer dose of 5 mg/kg intravenously at 0, 2, and 6 weeks then every 8 weeks
may have an increased immunosuppressive effect when combined with anti-psoriasis agents
may have an increased immunosuppressive effect when combined with anti-psoriasis agents
may have an increased immunosuppressive effect when combined with anti-psoriasis agents
may have an increased immunosuppressive effect when combined with anti-psoriasis agents
may have an increased immunosuppressive effect when combined with anti-psoriasis agents
When infliximab is used in combination with rabies vaccine, this leads to a reduction in the rabies vaccine effects through the process of pharmacodynamic antagonism
When infliximab is used in combination with diphtheria & tetanus toxoids, this leads to a reduction in the effects of diphtheria & tetanus toxoids through pharmacodynamic antagonism
pneumococcal vaccine 13-valent
infliximab diminishes the efficacy of the 13-valent pneumococcal vaccine through pharmacodynamic antagonism
when both drugs are combined, there may be an increased metabolism of etoposide
when both drugs are combined, the metabolism of paclitaxel increases when compared with infliximab
when both the drugs are combined, the metabolism of carmustine increases
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections
when both drugs are combined, there may be an increased risk of severe life-threatening infections
in combination with ofatumumab, infliximab increases the risk of adverse events
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections
when both drugs are combined, there may be an increased risk or severity of adverse effects
interaction raises immunosuppressive effects and risk of infection
may increase the toxic effect
may increase the immunosuppressive effect of anti-psoriatic agents
the toxicity of either of the drugs is increased by immunosuppressive activity
pneumococcal vaccine polyvalent
the activity of pneumococcal vaccine polyvalent is reduced due to pharmacodynamic antagonism
It may enhance the risk of adverse effects when combined with biologic agents
It may enhance the risk of adverse effects when combined with biologic agents
It may enhance the risk of adverse effects when combined with biologic agents
It may enhance the risk of adverse effects when combined with biologic agents
It may enhance the risk of adverse effects when combined with biologic agents
When acetohexamide is used together with infliximab, this lead to rise in acetohexamide’s metabolism
both the drugs increase the effect of immunosuppression risk of infection increases on administering both the drugs simultaneously
may increase the risk of adverse effects when combined
may increase the risk or severity of adverse effects when combined
It may enhance the adverse effects when combined with sotrovimab
Adverse drug reactions:
Frequency Defined
>10%
Infection (36%)
Infusion-related reaction (20%)
Headache (18%)
Abdominal pain (12%; 26% with Crohn disease)
Diarrhea (12%)
Upper respiratory tract infection (32%)
Nausea (21%)
1-10%
Rash (1-10%)
Bronchitis (10%)
Dyspepsia (10%)
Back pain (8%)
Rhinitis (8%)
Elevated ALT, ≥3 ULN (2-10%)
Fatigue (9%)
Urinary tract infection (8%)
Arthralgia
Fever
Pregnancy warnings:
AU TGA pregnancy category: C
US FDA pregnancy category: Not assigned
Lactation:
Excreted into human milk is unknown
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: infliximab
Why do we use infliximab?
infliximab is a Antirheumatics, TNF alfa inhibitors used to treat number of inflammatory autoimmune diseases and Ulcerative Colitis.